S1 Ep223: Optimizing Frontline Selection and Treatment-Free Remission in CML

S1 Ep223: Optimizing Frontline Selection and Treatment-Free Remission in CML

From Oncology On The Go by CancerNetwork

July 1, 2026 · 34 min · Season 1 · Episode 223

About this episode

Experts discuss the evolving frontline CML treatment landscape and strategies for achieving treatment-free remission.

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission. Once considered a terminal diagnosis, chronic myeloid leukemia (CML) in chronic phase has been fundamentally rewritten as a highly manageable chronic condition. In this episode of Oncology on the Go , Joshua Zeidner, MD, and Jorge E. Cortes, MD, sat down to explore the rapidly shifting therapeutic paradigm of frontline CML management. The discussion tracked the monumental evolution of treatment from early bone marrow transplants to the introduction of imatinib (Gleevec) and subsequent generations of tyrosine kinase inhibitors (TKIs). The experts dove deep into the practice-changing data from the phase 3 ASC4FIRST trial (NCT04971226), analyzing how the newly introduced STAMP inhibitor, asciminib (Scemblix), is challenging traditional treatment sequencing due to its superior efficacy and highly favorable toxicity profile. In the ASC4FIRST trial, the major molecular response (MMR) rate was 74.1% with asciminib vs 52.0% with other investigator-selected TKIs. The MMR rate at week 96 was consistently higher with asciminib vs other…

More episodes of Oncology On The Go

Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.